In HER2-positive breast cancer, the concomitant administration of the HER2 inhibitor lapatinib and the CDK4/6 inhibitor abemaciclib has demonstrated efficacy in suppressing breast cancer cells that exhibit resistance to lapatinib [75,76]. This evidence concerns the gene ERBB2 and breast carcinoma.